Mizuho Securities Downgrades Teva Pharma (TEVA) to Neutral
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mizuho Securities downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $45.00 (from $64.00), citing concerns over execution and a lack of catalysts.
Analyst Irina Koffler commented, "We downgrade TEVA to Neutral from Buy and lower our PT to $45 from $64. We missed earlier opportunities to downgrade as we awaited positive updates after the generics deal close, but that never materialized. Now TEVA faces a long integration period, headwinds from the Copaxone decision, and a dearth of meaningful catalysts. We are also concerned Teva could lower guidance, and want to avoid this risk by moving to the sidelines."
Shares of Teva Pharma closed at $44.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Upgrades Flowers Foods (FLO) to Hold
- Jefferies Cuts Price Target on GTx, Inc. (GTXI) to $7 Following Enobosarm Trial Results
- Jefferies Raises Price Target on Casey's General Stores (CASY) Following 2Q Earnings Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!